Blood Cancer J. 2023 May 26;13(1):87. doi: 10.1038/s41408-023-00856-0.
NO ABSTRACT
PMID:37230980 | DOI:10.1038/s41408-023-00856-0
Recent Content
- Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
- Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma
- Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines
- Comparison of trace elements in peripheral blood and bone marrow of newly diagnosed multiple myeloma patients
- Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma
- Single Question Can Predict Treatment Discontinuation in MM Patients
- Exploring the efficacy and safety of anti-BCMA chimeric antigen receptor T-cell therapy for multiple myeloma: Systematic review and meta-analysis
- Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
- Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria
- Current knowledge on therapeutic, diagnostic, and prognostics applications of exosomes in multiple myeloma: opportunities and challenges